May 2020: A federal judge decertified the class finding that several of the requirements for class certification were not met. The judge also denied the company’s motion for judgment as a matter of law concluding that questions remain about the product purchased, the circumstances of the purchase, and what the label said. Later in the month, the named plaintiff voluntarily dismissed this case without prejudice for undisclosed reasons.
February 2017: Quincy Bioscience moved for an order staying the proceedings in this action pending the resolution of the lawsuit filed against it by the Federal Trade Commission and New York Attorney General in January 2017 (FTC et al v. Quincy Bioscience Holding Co., Inc. et al.).
January 2015: A class-action lawsuit was filed against Quincy Bioscience, LLC for allegedly misleadingly marketing Prevagen, a brain health supplement. Specifically, the complaint alleges that the supplement is marketed as being “clinically tested” to “improve memory within 90 days” and support “healthy brain function, sharper mind, and clearer thinking” without scientific evidence to support such claims. (Racies et al v. Quincy Bioscience, LLC, Case No. 15-cv-00292, N.D. Cal.).
For more information about other class-action lawsuits and TINA.org’s coverage of them, click here.
When a complaint is dismissed without prejudice, an amended version of the complaint can be refiled.